Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Basic research into Parkinson’s

06.05.2004


Parkinson’s disease was first described in 1817 by the London physician James Parkinson. A great amount of research has been carried out since that time but the fundamental causes of the disease remain unresolved. Some time ago now researchers found that a neurotransmitter, dopamine, played a key role in this illness. This is why the majority of treatments used today to counter Parkinson’s increase the level of dopamine in the brain exciting the receptors of this neurotransmitter.

Animal models

Parkinson’s disease affects certain concrete cerebral nuclei in the human brain. These nuclei are the striated and the dark matter, nuclei which are related to the motor system. Parkinson’s disease specifically affects those neurones located between these cerebral nuclei.



So, when animals are used as models in order to analyse the illness, rats for example, lesions appear precisely at the location of these cerebral nuclei. The procedure involves introducing a toxic substance into specific co-ordinates of the rat’s brain, but only into one hemisphere thereof, the other remaining as a control or reference. In other words, so that the Parkinson’s is generated solely on one side of the animal’s brain.

Once the animal has recovered from the operation, after approximately one month, the analyses can begin. On the one hand, the behaviour of the animal is studied and analysed – the visible, external effects and, on the other, the effects of medication. In order to analyse the effects of the medication habitually used to treat the ailment, these medicines are administered and subsequently the electro-physiological activity of the brain is measured, i.e. the activity of the neurones. In this way it is intended to discover the medication most suitable to stop the progress of the disease.

Mild Parkinson’s

By the time Parkinson’s symptoms appear in humans, cerebral lesions are quite serious and the disease passed the point of no return. However, apparently, if the disease is managed to be detected at the early stages and applying a neurone protection treatment, the illness can be halted.

But, in this case, the validity of the medicines used presently is called into question. For example, the effects that the currently most commonly used treatment, levodopa. That is, it is not clear whether levodopa administered in the early stages of Parkinson’s is neuroprotector or neurotoxic. To this end, in order to analyse, amongst other factors, the effects that levodopa produce in the early stages of Parkinson’s, a model of mild Parkinson’s has been developed at the Leioa campus of the University of the Basque Country.

Obtaining rats with mild Parkinson’s is no easy task, given that the exact dose of the toxic substance has to be injected into the animal brain. Once a rat with mild Parkinson’s has been obtained, the usual medicines are administered and the animal monitored to see if there is a differentiated evolution in the disease or not. Thus, according the Leioa investigation, the effect of the medication is totally different depending if the rat is healthy, if it has mild Parkinson’s, or if the disease is advanced.

So, definite conclusions have yet to drawn, Moreover, in the case of Parkinson’s, soon we will have to start dealing with gene therapy or therapeutic cloning, given that these are the future paths to follow in order to counter the disease, according to the experts.

Garazi Andonegi | Basque research
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&Berri_Kod=461&hizk=I
http://www.ehu.es

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>